Kymera Therapeutics Q1 FY26 earnings call KYMR

Kymera Therapeutics celebrated its 10-year anniversary, marking a new chapter focused on delivering transformative medicines. The company has built unique capabilities in hit finding, identifying highly specific degraders, ensuring clinical translation, and derisking late-stage development. The guiding principles remain scientific focus, early proof-of-concept, and building medicines that change standard of care, with an ultimate goal of becoming a fully integrated global commercial company.

KT-621, a wholly-owned program, is positioned to fundamentally change the treatment paradigm in Type 2 inflammatory diseases like atopic dermatitis (AD) and asthma. Management believes KT-621 can offer the efficacy of biologics with the convenience of an oral pill, addressing the significant unmet need for patients currently untreated or undertreated. The company aims to expand the market rather than just taking share, targeting nearly 50 million patients who could benefit from better therapies.

KT-579, an IRAK5 degrader, is highlighted as a compelling program for autoimmune diseases like lupus, which are characterized by broad immune dysregulation. IRF5 is a genetically and biologically validated transcription factor that functions as a master regulator of immune responses. By selectively degrading IRF5, KT-579 has the potential to impact multiple key drivers of disease simultaneously, offering a more comprehensive and durable response compared to single-pathway biologics, with the convenience of oral dosing.

Gilead's decision to advance KT-200, Kymera's CDK2 molecular glue, into the clinic as early as next year, demonstrates the power of Kymera's R&D capabilities. This program targets CCNE-amplified tumors, addressing a challenge where CDK2 selective blockade has been difficult due to homology with CDK1. Kymera designed a highly selective molecular glue degrader outside the ATP binding pocket to achieve this specificity, showcasing its innovative approach to difficult-to-drug targets.

Kymera ended March with a strong cash balance of $1.55 billion, providing a runway into 2029. This capital is expected to fund both KT-621 Phase IIb trials in AD and asthma, a significant portion of the first KT-621 Phase III trial in AD, and advance KT-579 through initial proof-of-concept testing. The company is well-capitalized to progress its research pipeline, grow its organization, and build capabilities for later-stage development and commercialization.

The KT-621 Phase Ib BROADEN data presented at AAD reinforced its potential in AD, showing an overall mean reduction of Body Surface Area (BSA) of 49% at 4 weeks across two dose groups. This efficacy, along with EASI and pruritus improvements, was in line with published data for dupilumab at week 4. The data continues to highlight the potential for KT-621 as an effective and safe oral therapy for AD, resonating with KOLs and patient communities.